Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial-Reference-Cited by-同舟云学术

Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial

Published:2022-10-27 Issue:12 Volume:28 Page:2611-2621
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Bailón Lucia^ORCID,Llano Anuska^ORCID,Cedeño Samandhy^ORCID,Escribà Tuixent^ORCID,Rosás-Umbert Miriam^ORCID,Parera Mariona,Casadellà Maria^ORCID,Lopez Miriam,Pérez Francisco,Oriol-Tordera Bruna^ORCID,Ruiz-Riol Marta,Coll Josep,Perez Felix,Rivero Àngel,Leselbaum Anne R.,McGowan Ian^ORCID,Sengupta Devi,Wee Edmund G.,Hanke Tomáš^ORCID,Paredes Roger^ORCID,Alarcón-Soto Yovaninna^ORCID,Clotet Bonaventura^ORCID,Noguera-Julian Marc^ORCID,Brander Christian^ORCID,Molto Jose,Mothe Beatriz^ORCID,Barriocanal Ana María,Benet Susana,Cobarsi Patricia,Geleziunas Romas,Leselbaum Anne R.,Loste Cora,Meulbroek Michael,Miranda Cristina,Muñoz Jose,Naval Jordi,Nieto Aroa,Pujol Ferran,Puig Jordi,

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-02060-2.pdf

Reference49 articles.

1. Shan, L. et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491–501 (2012).

2. Mothe, B. et al. Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study). EClinicalMedicine 11, 65–80 (2019).

3. Mothe, B. et al. HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02). Front. Immunol. 11, 823 (2020).

4. Fidler, S. et al. Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet 395, 888–898 (2020).

5. Colby, D. J. et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat. Med. 26, 498–501 (2020).

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low prevalence of HIV in the northern Cameroon: contribution of some AIDS restriction genes and potential implications for gene therapy;Frontiers in Genetics;2024-09-13

2. HIV Vaccine Development at a Crossroads: New B and T Cell Approaches;Vaccines;2024-09-12

3. Biotech's role in advancing HIV vaccine development;Emerging Microbes & Infections;2024-08-12

4. The impact of analytical treatment interruptions and trial interventions on time to viral re‐suppression in people living with HIV restarting ART in cure‐related clinical studies: a systematic review and meta‐analysis;Journal of the International AIDS Society;2024-08

5. Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size;JCI Insight;2024-07-09